Physician profile
Aileen U Go
NPI 1144478421
$10,056.80
in general payments reported to CMS, 2019-2025
18 companies · $9,435 in 2025
The $9,435 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $13.41 · 2023: $174 · 2024: $105 · 2025: $9,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,680 · Consulting Fee: $3,475 · Food and Beverage: $1,369 · Travel and Lodging: $124 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,680.00 |
| Consulting Fee | $3,475.00 |
| Food and Beverage | $1,369.18 |
| Travel and Lodging | $124.22 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Autolus INC | $4,992.27 | 2025 | |
| Syndax Pharmaceuticals, INC. | $3,822.58 | 2025 | Revuforj |
| Celgene Corporation | $268.33 | 2019-2025 | Breyanzi |
| Cti Biopharma Corp. | $173.61 | 2023 | Vonjo |
| Kite Pharma, INC. | $125.87 | 2025 | Yescarta |
| Heron Therapeutics, INC. | $122.18 | 2025 | Aponvie, Zynrelef |
| Alexion Pharmaceuticals, INC. | $120.82 | 2019 | |
| Amgen INC. | $109.27 | 2019-2025 | Blincyto |
| Seagen INC. | $69.74 | 2019-2020 | |
| Incyte Corporation | $65.00 | 2024 | |
| Pfizer INC. | $53.11 | 2024-2025 | |
| Legend Biotech USA INC. | $23.25 | 2025 | Carvykti |
| Secura Bio, INC. | $22.61 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $19.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.29 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $18.69 | 2019 | |
| Merck Sharp & Dohme LLC | $15.33 | 2019 | |
| Abbvie INC. | $15.18 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aileen Go listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.